JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Lee, Yi F ^a   Miller, Lance D ^b   Chan, Xiu B ^a   Black, Michael A ^f   Pang, Brendan ^c   Ong, Chee W ^c   Salto Tellez, Manuel ^d,e   Liu, Edison T ^a,g   Desai, Kartiki V ^h  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g JACKSON LABORATORY   (United States)

^h NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; JMJD6 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKER; UNCLASSIFIED DRUG; HISTONE DEMETHYLASE; JMJD6 PROTEIN, HUMAN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MONOTHERAPY; ONCOGENE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN E; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MCF-7 CELLS; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKERS, BIOLOGICAL;

EID: 84861330841     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3200     Document Type: Article

References (38)

1. Soon WWML, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai K, Liu ET. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med 2011, 3:451-464. 10.1002/emmm.201100150, 21656687.
2. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RAB, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000, 405:85-90. 10.1038/35011084, 10811223.
3. Bose J, Gruber A, Helming L, Schiebe S, Wegener I, Hafner M, Beales M, Kontgen F, Lengeling A. The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. J Biol 2004, 3:15. 10.1186/jbiol10, 549712, 15345036.
4. Cui P, Qin B, Liu N, Pan G, Pei D. Nuclear localization of the phosphatidylserine receptor protein via multiple nuclear localization signals. Exp Cell Res 2004, 293:154-163. 10.1016/j.yexcr.2003.09.023, 14729065.
5. Chang B, Chen Y, Zhao Y, Bruick RK. JMJD6 Is a histone arginine demethylase. Science 2007, 318:444-447. 10.1126/science.1145801, 17947579.
6. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, Nielsen ML, Schmitz C, Butler DS, Yates JR, Delahunty CM, Hahn P, Lengeling A, Mann M, Proudfoot NJ, Schofield CJ, Böttger A. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 2009, 325:90-93. 10.1126/science.1175865, 19574390.
7. Boeckel J-N, Guarani V, Koyanagi M, Roexe T, Lengeling A, Schermuly RT, Gellert P, Braun T, Zeiher A, Dimmeler S. Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proc Natl Acad Sci USA 2011, 108:3276-3281. 10.1073/pnas.1008098108, 3044381, 21300889.
8. Hong X, Zang J, White J, Wang C, Pan CH, Zhao R, Murphy RC, Dai S, Henson P, Kappler JW, Hagman J, Zhang G. Interaction of JMJD6 with single-stranded RNA. Proc Natl Acad Sci USA 2010, 107:14568-14572. 10.1073/pnas.1008832107, 2930430, 20679243.
9. Team RDC R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2010, Team RDC.
10. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
11. Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127. 10.1093/biostatistics/kxj037, 16632515.
12. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
13. UNC Microarray Database. , https://genome.unc.edu/pubsup/breastGEO
14. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
15. SigmaPlot for Windows. 2008, Systat Software, Inc., San Jose, CA, 11.0.
16. Salto-Tellez M, Nga ME, Han HC, Wong AS, Lee CK, Anuar D, Ng SS, Ho M, Wee A, Chan YH, Soong R. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer 2007, 96:776-782. 10.1038/sj.bjc.6603551, 2360083, 17299397.
17. Das K, Mohd Omar MF, Ong CW, Bin Abdul Rashid S, Peh BK, Putti TC, Tan PH, Chia KS, Teh M, Shah N, Soong R, Salto-Tellez M. TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology 2008, 40:441-449. 10.1080/00313020802198101, 18604728.
18. PASW Statistics 18. 2009, Chicago: SPSS Inc., 18.0.0.
19. Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006, 66:11370-11380. 10.1158/0008-5472.CAN-06-2106, 17145883.
20. Ingenuity Systems. , http://www.ingenuity.com
21. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
22. Eisen M. TreeView 2002, 1.60.
23. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
24. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-2675. 10.1016/j.ejca.2004.08.021, 15571950.
25. Moses HL. TGF-beta regulation of epithelial cell proliferation. Mol Reprod Dev 1992, 32:179-184. 10.1002/mrd.1080320215, 1637556.
26. Robson CN, Gnanapragasam V, Byrne RL, Collins AT, Neal DE. Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol 1999, 160:257-266. 10.1677/joe.0.1600257, 9924195.
27. Ravitz MJWC. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res 1997, 71:165-207.
28. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993, 92:2569-2576. 10.1172/JCI116871, 288452, 7504687.
29. Ji H, Stout LE, Zhang Q, Zhang R, Leung HT, Leung BS. Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. J Cell Biochem 1994, 54:332-342. 10.1002/jcb.240540309, 8200913.
30. Fanayan S, Firth SM, Butt AJ, Baxter RC. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-β(TGF-β) and the type II TGF-β receptor. J Biol Chem 2000, 275:39146-39151. 10.1074/jbc.M006964200, 10993898.
31. Chen CR, Kang Y, Massagué J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proc Natl Acad Sci USA 2001, 98:992-999. 10.1073/pnas.98.3.992, 14697, 11158583.
32. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997, 124:2659-2670.
33. Geng Y, Weinberg RA. Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 1993, 90:10315-10319. 10.1073/pnas.90.21.10315, 47765, 7694291.
34. Moustakas A, Pardali K, Gaal A, Heldin C-H. Mechanisms of TGF-[beta] signaling in regulation of cell growth and differentiation. Immunol Lett 2002, 82:85-91. 10.1016/S0165-2478(02)00023-8, 12008039.
35. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995, 92:5545-5549. 10.1073/pnas.92.12.5545, 41732, 7777546.
36. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002, 347:1566-1575. 10.1056/NEJMoa021153, 12432043.
37. Spruck CH, Won K-A, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999, 401:297-300. 10.1038/45836, 10499591.
38. Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 2011, 108:3761-3766. 10.1073/pnas.1014835108, 3048107, 21321214.